Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blood bag safety

This article was originally published in The Gray Sheet

Executive Summary

Blood bag manufacturers Baxter, Med-Sec and Terumo are not specifically linked to the formation of white particulate recently found in collection bags in blood centers around the U.S., FDA says. An ongoing investigation initially focused on Baxter bags (1"The Gray Sheet" Feb. 10, 2003, In Brief). The agency notes that the particles are formed from natural substances within the blood and are possibly related to automated methods for platelet collection. The exact cause of particle formation is still unknown...

You may also be interested in...



Blood inspection guidance

FDA is working with Baxter, American Red Cross, CDC and state health authorities to investigate reports of white particulate found in approximately 100 Baxter blood bags. Interim guidance on visual inspection methods of all blood and blood components will be issued shortly, FDA notes Feb. 7, recommending Red Cross procedures such as "placing the bag, label down, on a flat counter undisturbed for 10 minutes and then performing a visual examination for particles." FDA reports receiving a "small number of adverse reports in patients who had also received transfusions utilizing such bags, including one fatality." Baxter said Feb. 3 the particulate is "blood-derived in nature [and] likely a very small fibrin clot containing white blood cells and platelets." Red Cross quarantined 70% of the blood inventory in its southern region and shipped approximately 3,000 new units to Atlanta and 500 units to the Tennessee Valley...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
UsernamePublicRestriction

Register

MT017956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel